Glioblastoma multiforme (GBM) are among the most devastating neoplasms claiming 
the lives of patients within a median of 1 year after diagnosis. Treatment of 
GBM requires a multidisciplinary approach. Treatments include surgery, 
radiotherapy, chemotherapy and so on. Temozolomide (TMZ) has emerged as an 
active agent against malignant gliomas. On the basis of the work by the European 
Organisation for Research and Treatment of Cancer/National Cancer Institute of 
Canada, concurrent radiotherapy and the oral alkylating agent TMZ followed by 
adjuvant TMZ has become the standard of care for patients with newly diagnosed 
GBM, although the methylation status of the O(6)-mehylguanine-DNA 
methyltransferase promoter is predictive for survival of GBM patients. Gliadel 
is a biodegradable polymer wafer impregnated with carmustine. Gliadel has been 
one of the few treatment modalities to demonstrate a statistical benefit in 
patients with malignant glioma. These new FDA approved drugs advanced the 
treatment of malignant glioma, but more progress is needed. Patients require 
improvements in chemotherapy, surgery, radiotherapy, molecular targeted therapy, 
immunotoxin using the convection-enhanced delivery and more.